#ESMO26 Day 4: Midday Update
Lung cancer leads. TILs enter the sarcoma conversation.
$HCM $AZN: SANOVO, Phase 3. Savolitinib + osimertinib: 24.9 vs. 13.8 months PFS in first-line EGFR-mutant, MET-overexpressing NSCLC.
$BMY: PANKU-Lung01, Phase 3. Bispecific ADC iza-bren: 11.1 vs. 5.7 months PFS after EGFR-TKIs. OS immature.
$EIKN: Phase 2 EIK1001 + chemoimmunotherapy: 72.4% responses in squamous NSCLC. Uncontrolled, n=29.
$IOVA: Lifileucel TIL therapy: 4/8 responses in a sarcoma pilot, all ongoing at cutoff.
Big Phase 3 gains. Early signals worth watching.
What to watch this afternoon 👇🏻
863 浏览 · 3 赞 · 2 转发 · 2 回复
👀Now comes Monday’s market reaction! Which ticker will make the biggest move after the weekend's ESMO readouts?在 X 查看被引用的帖子
- BiopharmIQ by Amp@BiopharmIQ
Who will be the big mover today? Explore BPIQ’s prob/mag scenarios 👇 https://www.offers.bpiq.com/probability-move-analysis?mo=oct6
- BiopharmIQ by Amp@BiopharmIQ
👀 Afternoon watch: $INCY’s Phase 1 KRAS G12D combo in pancreatic cancer; $GSK/Hansoh’s Phase 3 B7-H3 ADC in osteosarcoma; and $MRK’s two Phase 3 endometrial cancer readouts: TroFuse-005 + KEYNOTE-C93. #ESMO26
来源：BiopharmIQ by Amp · x.com